Atlas Trials

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Clinical trial NCT01342913 · COMPLETED

Trial details

NCT number
NCT01342913
Sponsor
GlaxoSmithKline
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Pulmonary Disease, Chronic Obstructive
Start date
2011-02-01
Primary completion
2011-10-01
Enrollment
528

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.